2015 Volume 58 Issue 4 Pages 279-285
We examined the efficacy and safety of switching to basal-bolus insulin therapy in patients with type 2 diabetes treated with the three-injection method using premixed insulin. The patients were assigned to receive either titration by a physician (PT) or self-titration (ST) and subsequently classified into the insulin glargine (Gla) +insulin glulisine (Glu) group or insulin detemir (Det) +insulin aspart (Asp) group. At 24 weeks after switching, the HbA1c levels decreased from 8.46 % to 7.81 % (P<0.001). Regarding the titration method, there was a tendency to obtain better control with the ST method. In terms of the formulations, a greater improvement in the HbA1c values was seen in the Gla+Glu group. We then conducted a survey on treatment satisfaction before and after switching the therapies; however, no deterioration in the scores was noted. Switching to basal-bolus therapy from the three-injection method is useful.
